

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10597720	
	Filing Date		2006-11-04	
	First Named Inventor	Maliken Bayrakdarian		
	Art Unit			
	Examiner Name			
	Attorney Docket Number		133087.11201(101215-1PUS)	

U.S.PATENTS							Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1	5866573		1999-02-02	Sanderson et al.			
	2	5668289		1997-09-16	Sanderson et al.			
	3							
If you wish to add additional U.S. Patent citation information please click the Add button.							Add	
U.S.PATENT APPLICATION PUBLICATIONS							Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1							
If you wish to add additional U.S. Published Application citation information please click the Add button.							Add	
FOREIGN PATENT DOCUMENTS							Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² i	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	97/40024	WO		1997-10-30	Merck & Co., Inc.		<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10597720
Filing Date		2006-11-04
First Named Inventor	Maliken Bayrakdarian	
Art Unit		
Examiner Name		
Attorney Docket Number	133087.11201(101215-1PUS)	

	2	96/31504	WO		1996-10-10	Merck & Co., Inc.		<input type="checkbox"/>
	3	02/28825	WO		2002-04-11	3-Dimensional Pharmaceuticals, Inc.		<input type="checkbox"/>
	4	02/064140	WO		2002-08-22	Merck & Co., Inc.		<input type="checkbox"/>
	5	97/01338	WO		1997-01-16	Merck & Co., Inc.		<input type="checkbox"/>
	6	1308511	EP		2003-05-07	Mermaid Pharmaceuticals GmbH		<input type="checkbox"/>
	7	19705012	DE		1998-08-13	Hoeshst Schering AgrEvo GmbH		<input type="checkbox"/>
	8	56128769	JP		1981-10-08	Taiho Yakuhin Kogyo K. K.		<input type="checkbox"/>
	9	95/35313	WO		1995-12-28	Corvas International, Inc.		<input type="checkbox"/>
	10	02/057225	WO		2002-07-25	Merck & Co., Inc.		<input type="checkbox"/>
	11	03/048155	WO		2003-06-12	University of Ljubljana		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

Add

NON-PATENT LITERATURE DOCUMENTS

Remove

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10597720
Filing Date	2006-11-04
First Named Inventor	Maliken Bayrakdarian
Art Unit	
Examiner Name	
Attorney Docket Number	133087.11201(101215-1PUS)

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
	1	Koetzer, W., "N-Amino derivatives of uraciles. II. N-3-aminouracil" , Monatshefte fuer Chemie, 1966, 97 (4):1117-1124.	<input checked="" type="checkbox"/>
	2	Simon, Barbara, et al., "Ring cleavage of 1,3,4-oxadiazolo(3,2-a)pyrimidinones by ethyl carbazate", Zeitschrift fuer Chemie, 1972, 12(1): 20-1.	<input type="checkbox"/>
	3	Gehlen, H. et al., "[2amino-1,3,4-oxadiazoles. XXXV . Synthesis and reaction of 1,3,4-oxadiazolo(3,2-a)pyrimidinones", Arch. Pharm. Ber Dtsch. Pharm. Ges., 1970, 303(12):945-55.	<input type="checkbox"/>
	4	Yamashita, J., et al., "Studies on Antitumor Agents. V. 1) Syntheses and Antitumor Activities of 5-Fluorouracil Derivatives", Chem. Pharm. Bull., 1982, 30:4258-4267.	<input type="checkbox"/>
	5	Marunaka, T., "Mass Spectra of N-Substituted Derivatives of 5-Fluorouracil", Biomedical Mass Spectrometry, 1981, 8 (3):105-110.	<input type="checkbox"/>
	6	Hanessian, S. et al., "Targeting Thrombin and Factor VIIa: Design, Synthesis, and Inhibitory Activity of Functionally Relevant Indolizidinones", Bioorganic & Medicinal Chemistry Letters, 2002, 12:2907-2911.	<input type="checkbox"/>
	7	Office Action dated September 7, 2007 (U.S. Serial No. 10/596506)	<input type="checkbox"/>
	8	Notice of Co-Pending Applications.	<input type="checkbox"/>
	9	Szurdoki, F., et al., "Synthesis of Haptens and Protein Conjugates for the Development of Immunoassays for the Insect Growth Regulation Fenoxycarb", J. Agric. Food Chem., 50:29-40, 2002.	<input type="checkbox"/>
	10	Gilissen, C., et al., "Synthesis of N-(2-[18F]fluoroethyl)-N9-methylthiourea: a hydrogen Peroxide scavenger", J. Labelled Cpd. Radiopharm., XLI:491-502, 1998.	<input type="checkbox"/>

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10597720
	Filing Date		2006-11-04
	First Named Inventor	Maliken Bayrakdarian	
	Art Unit		
	Examiner Name		
	Attorney Docket Number	133087.11201(101215-1PUS)	

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE			
---------------------------	--	--	--

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.